MACK RSI Chart
Last 7 days
0.3%
Last 30 days
0.6%
Last 90 days
12.5%
Trailing 12 Months
29.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2019 | 0 | 2.8M | 3.8M | 4.9M |
2017 | 0 | 96.7M | 49.2M | 1.7M |
2016 | 95.7M | 92.8M | 104.5M | 144.3M |
2015 | 104.6M | 113.3M | 101.7M | 89.3M |
2014 | 46.2M | 55.5M | 76.7M | 102.8M |
2013 | 52.2M | 58.6M | 54.2M | 47.8M |
2012 | 39.1M | 44.6M | 47.3M | 48.9M |
2011 | 23.8M | 27.3M | 30.7M | 34.2M |
2010 | 0 | 0 | 0 | 20.3M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Dec 28, 2023 | andersen eric | bought | 11,441 | 13.3503 | 857 | - |
Dec 26, 2023 | andersen eric | bought | 640,313 | 13.15 | 48,693 | - |
Dec 07, 2023 | andersen eric | bought | 1,298,470 | 12.8498 | 101,050 | - |
Nov 17, 2023 | andersen eric | bought | 3,750 | 12.5 | 300 | - |
Nov 14, 2023 | andersen eric | bought | 627,125 | 12.5 | 50,170 | - |
Nov 13, 2023 | andersen eric | bought | 192,875 | 12.3876 | 15,570 | - |
Nov 10, 2023 | andersen eric | bought | 469,008 | 12.3222 | 38,062 | - |
Nov 09, 2023 | andersen eric | bought | 121,618 | 12.1923 | 9,975 | - |
Nov 08, 2023 | andersen eric | bought | 167,701 | 12.132 | 13,823 | - |
Aug 11, 2023 | crocker gary l | bought | 24,865 | 12.4326 | 2,000 | see remarks |
Which funds bought or sold MACK recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | new | - | 107 | 107 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 1.43 | 763,832 | 8,166,070 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 101 | 513,013 | 943,984 | -% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | reduced | -0.4 | 5,362 | 69,786 | -% |
Feb 16, 2024 | Madison Avenue Partners, LP | unchanged | - | 597,332 | 7,416,870 | 1.05% |
Feb 15, 2024 | Legal & General Group Plc | unchanged | - | 1,389 | 17,245 | -% |
Feb 15, 2024 | BARCLAYS PLC | added | 679 | 170,000 | 193,000 | -% |
Feb 14, 2024 | BANK OF AMERICA CORP /DE/ | added | 106 | 93,301 | 167,947 | -% |
Feb 14, 2024 | Metropolitan Life Insurance Co/NY | unchanged | - | 627 | 7,791 | -% |
Feb 14, 2024 | KENNEDY CAPITAL MANAGEMENT LLC | reduced | -50.7 | -535,851 | 619,569 | 0.01% |
Unveiling Merrimack Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Merrimack Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 42.3B | 6.8B | -8.96 | 6.17 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.4B | 1.8B | -44.17 | 10.64 | ||||
BMRN | 16.7B | 2.4B | 99.73 | 6.91 | ||||
INCY | 12.8B | 3.7B | 21.46 | 3.47 | ||||
MID-CAP | ||||||||
APLS | 7.1B | 396.6M | -13.34 | 17.78 | ||||
BBIO | 5.4B | - | -8.31 | 60.35 | ||||
AXSM | 3.8B | 270.6M | -15.68 | 13.86 | ||||
ARWR | 3.6B | 240.7M | -11.98 | 14.77 | ||||
ACAD | 3.0B | 726.4M | -48.93 | 4.13 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 398.2M | 26.85 | 4.82 | ||||
NVAX | 678.8M | 983.7M | -1.25 | 0.69 | ||||
CRBP | 373.2M | 881.7K | -8.37 | 466.16 | ||||
INO | 304.5M | 4.9M | -2.25 | 62.57 | ||||
IBIO | 11.8M | 2.1M | -0.43 | 2.14 |
Merrimack Pharmaceuticals Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2019Q4 | 2019Q3 | 2019Q2 | 2017Q4 | 2017Q3 | 2017Q2 | 2016Q4 | 2016Q3 | 2016Q2 | 2016Q1 | 2015Q4 | 2015Q3 | 2015Q2 | 2015Q1 | 2014Q4 | 2014Q3 | 2014Q2 | 2014Q1 | 2013Q4 | 2013Q3 | 2013Q2 |
Revenue | - | - | - | 1.00 | - | 20.00 | 41.00 | 61.00 | 28.00 | 34.00 | 21.00 | 21.00 | 16.00 | 37.00 | 15.00 | 34.00 | 28.00 | 28.00 | 13.00 | 8.00 | 7.00 | 18.00 |
Cost Of Revenue | - | - | - | - | - | - | - | 3.00 | 1.00 | 2.00 | 1.00 | 0.00 | - | - | - | - | - | - | - | - | - | - |
Costs and Expenses | - | - | - | - | 17.00 | 17.00 | 35.00 | 42.00 | 36.00 | 36.00 | 34.00 | -9.63 | 55.00 | 55.00 | 45.00 | 39.00 | 52.00 | 42.00 | 37.00 | 36.00 | 43.00 | 48.00 |
Operating Expenses | 161.3% | 2.00 | 1.00 | 9.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
S&GA Expenses | -49.1% | 2.00 | 4.00 | 6.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
R&D Expenses | - | - | - | 5.00 | 12.00 | 14.00 | 20.00 | 26.00 | 28.00 | 28.00 | 28.00 | 38.00 | 30.00 | 26.00 | 26.00 | 31.00 | 44.00 | 34.00 | 30.00 | - | - | - |
Interest Expenses | - | 0.00 | - | 1.00 | 4.00 | 2.00 | 27.00 | 2.00 | 2.00 | 16.00 | 3.00 | 5.00 | 4.00 | 4.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 4.00 | - | - |
Income Taxes | - | - | - | - | -10.03 | -2.13 | -30.24 | - | -9.77 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | -Infinity% | -2.15 | - | - | -21.86 | -7.46 | -59.88 | -43.54 | -36.61 | -51.63 | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | 562.6% | 3.00 | -0.70 | -9.43 | -12.95 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -0.6% | 19.00 | 19.00 | 19.00 | 20.00 | 20.00 | 14.00 | 14.00 | 15.00 | 15.00 | 15.00 | 16.00 | 16.00 | 17.00 | 19.00 | 20.00 | 21.00 | 20.00 | 25.00 | 45.00 | 74.00 | 89.00 |
Current Assets | -0.6% | 19.00 | 19.00 | 19.00 | 20.00 | 20.00 | 14.00 | 14.00 | 15.00 | 15.00 | 15.00 | 16.00 | 16.00 | 17.00 | 19.00 | 19.00 | 20.00 | 19.00 | 22.00 | 43.00 | 64.00 | 76.00 |
Cash Equivalents | -1.5% | 6.00 | 6.00 | 10.00 | 19.00 | 19.00 | 13.00 | 13.00 | 14.00 | 14.00 | 15.00 | 15.00 | 14.00 | 14.00 | 16.00 | 16.00 | 18.00 | 17.00 | 21.00 | 37.00 | 37.00 | 21.00 |
Net PPE | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00 | 2.00 |
Liabilities | -10.5% | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 3.00 | 3.00 | 5.00 | 5.00 | 25.00 | 30.00 |
Current Liabilities | -10.5% | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 3.00 | 3.00 | 5.00 | 5.00 | 12.00 | 15.00 |
Shareholder's Equity | -0.3% | 19.00 | 19.00 | 19.00 | 19.00 | 19.00 | 13.00 | 14.00 | 14.00 | 14.00 | 15.00 | 15.00 | 16.00 | 16.00 | 17.00 | 17.00 | 18.00 | 17.00 | 20.00 | 40.00 | 49.00 | 59.00 |
Retained Earnings | 0.0% | -548 | -548 | -548 | -547 | -547 | -547 | -546 | -546 | -546 | -545 | -545 | -544 | -543 | -542 | -541 | -540 | -540 | -543 | -543 | -533 | -523 |
Additional Paid-In Capital | 0.0% | 566 | 566 | 566 | 566 | 566 | 559 | 559 | 559 | 559 | 559 | 559 | 559 | 558 | 558 | 558 | 557 | 557 | 563 | 582 | 581 | 581 |
Shares Outstanding | 0.2% | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | - | - | - | 57.00 | - | - | - | 68.00 | - | - | - | 44.00 | - | - | - | 79.00 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -20.3% | -273 | -227 | -644 | -356 | -185 | -264 | -939 | -354 | -355 | -445 | 1,019 | -437 | -1,776 | 135 | -1,979 | -1,005 | -2,640 | -3,203 | -11,873 | -13,652 | -18,892 |
Cashflow From Investing | 101.8% | 68.00 | -3,845 | -8,811 | 139 | - | - | - | 445 | - | 94.00 | - | 50.00 | - | - | -311 | 2,450 | 5,000 | 6,500 | 28,210 | 30,115 | -10,823 |
Cashflow From Financing | - | 133 | - | 209 | 179 | - | - | - | - | - | - | - | 239 | - | - | - | - | -6,638 | -19,940 | - | - | - |
Dividend Payments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6,700 | - | - | - | - |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating expenses: | ||
General and administrative expenses | $ 2,176 | $ 2,174 |
Gain on sales of assets | (139) | (445) |
Total operating expenses | 2,037 | 1,729 |
Loss from operations | (2,037) | (1,729) |
Other income and expenses: | ||
Interest income | 868 | 188 |
Total other income and expenses | 868 | 188 |
Loss before income tax expense | (1,169) | (1,541) |
Income tax expense | (12) | (3) |
Net loss and comprehensive loss | $ (1,181) | $ (1,544) |
Net loss per common share - basic | $ (0.08) | $ (0.11) |
Net loss per common share - diluted | $ (0.08) | $ (0.11) |
Weighted-average common shares used to compute basic net loss per common share | 14,299 | 13,524 |
Weighted-average common shares used to compute diluted net loss per common share | 14,299 | 13,524 |
Consolidated Balance Sheets - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 5,989,000 | $ 19,439,000 |
Short-term investments | 12,886,000 | 0 |
Prepaid expenses and other current assets | 309,000 | 389,000 |
Total current assets | 19,184,000 | 19,828,000 |
Other assets | 4,000 | 8,000 |
Total assets | 19,188,000 | 19,836,000 |
Current liabilities: | ||
Accounts payable, accrued expenses and other | 441,000 | 589,000 |
Total current liabilities | 441,000 | 589,000 |
Total liabilities | 441,000 | 589,000 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock, $0.01 par value: 10,000 shares authorized at December 31, 2023 and 2022 no shares issued or outstanding at December 31, 2023 or 2022 | ||
Common stock, $0.01 par value: 30,000 shares authorized at December 31, 2023 and 2022; 14,351 and 14,215 shares issued and outstanding at December 31,2023 and 2022 | 1,343,000 | 1,342,000 |
Additional paid-in capital | 566,221,000 | 565,541,000 |
Accumulated deficit | (548,817,000) | (547,636,000) |
Total stockholders’ equity | 18,747,000 | 19,247,000 |
Total liabilities and stockholders’ equity | $ 19,188,000 | $ 19,836,000 |